Depression With Dystonia Predicts Lower Quality of Life

Daniel M. Keller, PhD

September 26, 2019

NICE, France — Depression is the strongest long-term predictor of health-related quality of life (HR-QoL), followed by generalized anxiety disorder (GAD), for patients with isolated dystonia, a new study shows.

Dystonia motor severity only predicted social functioning, researchers found. Isolated dystonia is dystonia with or without tremor but without other neurologic findings.

"With the path model, we saw that really depressed symptoms predicted quality of life on any of the domains, so, more depression, the lower quality of life is," senior author Norbert Brüggemann, MD, from the University of Luebeck, Germany, reported here on a poster tour session at the International Congress of Parkinson's Disease and Movement Disorders (MDS) 2019.

In the eight-lagged path models, several variables were compared at different time points to assess for associations with HR-QoL, using the RAND 36-Item Short Form Health Survey involving eight different domains.

Longitudinal assessments of 155 patients (of a total of 603 enrolled) were performed at baseline and at 1 and 2 years' follow-up. At least 2 months elapsed between botulinum injections and the assessments.

Depression and anxiety were rated using the Hamilton Anxiety Depression Scale. The Liebowitz Social Anxiety Scale was used to rate social anxiety. Correlations were made with regard to patients' sex and age but not the type of dystonia, because of lack of power of the study.

Higher baseline depression scores predicted lower HR-QoL on all eight domains measured (P < .001). For generalized anxiety, as assessed by the Hamilton score, "we found out that there is also an effect on quality of life, but only in three different categories with regard to general health, pain, and emotional well-being," Brüggemann said.

There was also an association with social anxiety, he said, "but interestingly enough, higher anxiety scores were correlated to a better quality of life in terms of pain-related dystonia" after 2 years (all P < .006).

The motor component of dystonia, as rated by the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), predicted HR-QoL only in the context of social functioning (P = .002). Neither dystonic tremor, age, nor sex correlated with HR-QoL.

In summary, he said that HR-QoL "was really dominated by depression."

With regard to two classes of patients, those with higher QoL and those with lower QoL over time, the investigators found that the patients with the higher QoL were more susceptible to depression and social anxiety disorder and that the patients with lower QoL were more susceptible to GAD.

"So our conclusion from this is really that depression has a very severe impact on QoL, not only cross-sectionally but also for the long run, and has to be treated specifically," Brüggemann said.

Stanley Fahn, MD, Columbia University, New York City, who was a guide for the poster tour, commented that he feels that "having a lot of depression and anxiety ruins everybody's quality of life. You don't have to have dystonia. So I think these are epiphenomena to the dystonia."

He described a patient he had seen who had severe Parkinson disease but had very good quality of life because "she learned to live with it and had an assistant." He said that in his estimation, with regard to quality of life, much "has to do with the psyche, what you think your quality of life is...rather than the motor scales." Fahn is a co-developer of the BFMDRS.

In answer to a question from Fahn as to whether HR-QoL improves with the use of botulinum toxin to treat the dystonia, Brüggemann said scores initially improved but then decreased.

Brüggemann noted some limitations of the study:

  • Only the presence and not the severity of dystonic tremor was evaluated.

  • Although the BFMDRS is a validated and commonly used rating scale for dystonia, it may not be representative for focal dystonias, for which its scores are low.

  • Because of limited longitudinal data, the type of dystonia and socioeconomic background could not be assessed as potentially predictive factors for HR-QoL. Similarly, the lack of power prevented an assessment of any benefit from treatment of anxiety or depression.

Nonetheless, he recommended treating anxiety and depression in hope of raising HR-QoL.

Another study on the same poster tour reached similar conclusions. Ihedinachi Ndukwe, MD, University College Dublin, Ireland, found that for cervical dystonia, a clinical history of anxiety and/or depression was associated with more distress in relation to pain, disability, anxiety, and depression, with greater impairment of HR-QoL.

The study received no commercial funding. Brüggemann received speaker's honoraria from Grünenthal, UCB, AbbVie, and Teva and served as a consultant for Censa Pharmaceuticals. He is funded by the DFG, the Collaborative Center for X-linked Dystonia-Parkinsonism, and the Else-Kröner Fresenius-Stiftung. Fahn has consulted for and is a member of the advisory board with honoraria for Merz Pharma, Genervon Biotechnology, PixarBio, and Lundbeck Pharma and has received grants/research support from Genervon Biotechnology.

International Congress of Parkinson's Disease and Movement Disorders (MDS) 2019: Abstracts 1293 and 1323, presented September 24, 2019.

For more Medscape Neurology news, join us on Facebook and Twitter


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.